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Summary.-Monocyte-mediated antibody-dependent cellular cytotoxicity (ADCC)
was tested in 23 patients with histologically proven Hodgkin's disease and 29 healthy
normal controls. Seven patients presented with active and 16 with inactive disease.
The lytic capacity of the individual monocytes was significantly (P<002) higher in
patients with Hodgkin's disease than in normals. However, no significant difference
was found between the numbers of monocytes in both groups of individuals, as
determined by non-specific esterase staining. No correlation was found between the
lytic capacity of monocytes and the activity of the disease.
PATIENTS with Hodgkin's disease (HD)
frequently exhibit impaired cell-mediated
immunity (Aisenberg, 1965). Recent in-
vestigations indicate an anergy to recall
antigens, failure of dinitrochlorobenzole
sensitization, impaired mitogen reactivity
(Case et al., 1976; Eltringham & Kaplan,
1973) and reduced proliferation in mixed
lymphocyte cultures (Bjorkholm et al.,
1976; Twomey et al., 1975). In addition,
lymphopenia (Young et al., 1972) and
lower percentages of T lymphocytes
(Colmen et al., 1973) have been reported.
Data on monocyte function in HD are
rare, though the Reed-Sternberg cell
seems to be of macrophage origin (Kadin
et al., 1978). Reduced phagocytic activity
of monocytes (Urbanitz et al., 1975),
decreased chemotactic response and mono-
cyte bactericidal activity (Leb & Merritt,
1978) have been reported. We studied
monocyte-mediated antibody-dependent
cellular cytotoxicity (ADCC) in patients
with HD in order to investigate a further
parameter of monocyte function. In-
creased ADCC of monocytes was detected
in HD by using a particular in vitro ADCC
system, in which antibody-coated human
erythrocytes are killed by peripheral-
blood monocytes (Holm & Hammarstrom,
1973; Poplack et al., 1976; Pehamberger
et at., 1980; Nyholm & Currie, 1978).
MATERIALS AND METHOD)S
Patients. 23 patients (13 male, 10 female;
age range 16-42 years, mean 32+663) with
histologically proven HD wxere investigated.
All patients exhibited Stage III or IV of the
disease, 7 presenting wNith active and 16 with
inactive disease. Since depression ofmonocyte
function may occur shortly after drug inges-
tion (Leb & Merritt, 1978) care was taken that
none of the patients had received any cyto-
static treatment for the last 3 weeks before
investigation. In addition, none ofthe patients
had active intercurrent infections when the
study was performed. 29 normal, sex- and
age-matched healthy volunteers served as
controls.
Effector cells. Mononuclear cell (MNC) sus-
pensions wiere obtained by Ficoll-Hypaque
separation and were washed x 3 in RPMI
1640 (Flow Laboratories, Bonn, XV. Germany),
supplemented writh 1000 heat-inactivated
foetal calf serum (Flow Laboratories). The
proportion of monocytes in the MNC prepara-
tion was evaluated by non-specific esterase
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(NSE) staining according to Koski et al.
(1976).
Target cells-.Group B human red blood
cells (HRBC, Immuno-AG, Vienna, Austria),
were labelled with 100 /Ci sodium [51Cr]
chromate (Behring-Werke, W. Germany)
washed x 3 in medium and resuspended to a
concentration of 5 x 107 HRBC/ml medium.
Antibody.-Heat-inactivated humanhyper-
immune antiserum to Group B-HRBC
(Schwab Laboratories, Vienna, Austria) was
used in a final dilution of 1:50 in all experi-
ments, exhibiting a haemagglutination titre
of 1/160.
ADCC microassay.-Serial dilutions of
MNC ranging from 4 0 to 1P0 x 105 in 160 ,ul
medium were incubated in round-bottomed
wells of microplates (Nunc Laboratories,
Roskilde, Denmark) at 37°C for 20 h in a
humid atmosphere, with 106, 51Cr-labelled
B-HRBC in 20 ,l, in the presence of 20 pl of
the diluted anti-B serum. After incubation,
the radioactivity of the supernatants, har-
vested by Titertex system (Flow Labora-
tories) was determined in a gamma scintilla-
tion counter (Nuclear Chicago, Chicago,
U.S.A.). The results were then expressed as
percentage 5lCrreleaseaccording theformula:
%51Cr release =
release in test well -spontaneous release
total releasable -spontaneous release
The total releasable %51Cr was measured
after the addition of 180 ,ul distilled water to
the HRBC and the spontaneous %51Cr
release after addition of20 pl medium instead
of the antiserum. Controls included the
measurement of the lytic activity of the
antiserum and of the medium alone. All
experiments were done in triplicate and the
values for %51Crrelease represent the mean +
the standard error of the mean. Experiments
were excluded when the spontaneous %51Cr
release, the lytic activity of the antiserum or
the medium alone exceeded 10% of the total
releasable 51Cr, or when the standard error
of the %51Cr release exceeded 10% of the
mean.
Statistical analysis.-The correlation be-
tween NSE+ cells and %/051Cr release was
tested by linear correlation analysis. Student's
t test was used for comparison of log trans-
formed ADCC values between patients and
controls. In addition, the %51Cr release per
103 NSE+ cells was determined in each
individual and the mean values of patients
and controls were compared using Student's
t test for paired values.
RESULTS
The lytic capacity of monocytes was
tested in the ADCC system at 3 MNC:
target cell ratios: 1: 2-5, 1:5, 1: 10 respec-
tively. A significant correlation (P < 0.05)
was found between the number of NSE+
cells and the percentage %51Cr release in
both patients and normals at all the ratios
tested (patients: median (m) = 1846, range
(r)=5-50; normals: m= 17-0, r=5 0-
49.0). The O/15 Cr release, representing the
lytic capacity of monocytes was signifi-
cantly higher (P<0.02, <0-001, <04001
respectively) in patients than in the nor-
mals, at all 3 MNC:target cell ratios
(Table). No correlation was found between
the lytic capacity of monocytes and the
activity ofthe disease in the patients. The
lytic capacity of the individual monocytes
was calculated as the %51Cr release/103
monocytes, and was significantly higher
in patients with HD than in controls
(P < 0-02. Figure). The proportion of
monocytes of the MNC fraction was
evaluated by NSE staining and was found
not to be significantly different between
TABLE.-Monocyte-mediated ADCC in patients with Hodgkin's disease and in controls
MNC: target
cell ratio
1 :2-5
1:5
1:10
0,/51Cr release*
C-
Patients Controls
76-5 (84 9-94 4) 51-5 (21-1-91-2)
46-5 (16-1-84-4) 30 7 (11.0-63 6)
25-0 (7 6-49 7) 15-5 (6-6-31-3)
* Median (range).
t Student's t test on log-transformed values.
Pt
<0 02
<0-001
<0-001
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Fie. 0%51Cr release/103 monocytes signifi-
cantly greater (P < 0.02) in patients with
Hodgkin's disease than in controls.
patients (22.07 T 2.5) and healthy indi-
viduals (19.7 + 1.7).
DISCUSSION
Malignant tumours frequently stimu-
late formation of, or are surrounded by, a
mononuclear cell infiltrate (Gauci, 1975;
Kjeldsberg & Pay, 1978) leading to the
speculation that an attempt is made by
the host to counter neoplastic invasion
(Evans, 1976). A strong mononuclear reac-
tion has been found to be associated with
a more favourable clinical prognosis
(Kjeldsberg & Pay, 1978). In patients with
malignancies, especially those with rapidly
progressive disease, several defects in the
monocyte/macrophage system have been
reported (Dizon & Southam, 1963; Evans,
1976; Currey & Hedley, 1977; Snyderman
et al., 1977). Moreover, monocyte abnor-
malities in cancer patients have been
shown to be associated with poor prog-
nosis (Normann et al., 1979). Thus, the
monocyte/macrophage system seems to
play an important role in immune sur-
veillance.
The cytolytic activity of monocytes
against tumour cell is an important func-
tion of this cell type, besides its chemo-
tactic, phagocytic, bactericidal and
immuno-regulatory activity in the im-
mune defence mechanism. In 1973, Holm
& Hammarstrom described a test for the
cytolytic activity of monocytes in which
peripheral-blood monocytes lyse antibody-
coated 51Cr-labelled human erythrocytes.
The erythrolysis represents the lytic
activity of the monocytes, and this assay
is now regarded as a useful test for this
particular monocyte function (Nyholm &
Currie, 1978; Poplack et al., 1976; Peham-
berger et al., 1980). In previous experi-
ments (Pehamberger et al., 1980) the
monocyte nature of the effector cells in
this particular test system had been fur-
ther confirmed by enrichment (plastic
dishes) and depletion (nylon wool) of
adherent cells, X-irradiation, and pre-
treatment with carageenan and heat-
aggregated IgG. In the present study this
assay was applied in order to investigate
monocyte-mediated ADCC in HD.
The percentage of monocyte-mediated
51Cr release was found to be significantly
greater in patients with HD than in
normals. Absolute numbers of monocytes,
as determined by NSE staining, were not
significantly different in both groups of
individuals. In order to compare the lytic
activity of the individual monocytes, the
values ofthe 0%51Cr release/103 monocytes
of patients and controls were paired for
statistical comparison. Thereby a possible
bias due to the different individual mono-
cyte:target cell ratios was eliminated. The
0%51Cr release/103 monocytes was signifi-
cantly greater in patients with HD than in
controls. With regard to the fact that no
significant difference was found between
the absolute numbers of monocytes in
patients with HD and in normals, these
results indicate that the lytic activity of
the individual monocytes is increased in
patients with HD. Interestingly, the cyto-
780
I
0MONOCYTE-MEDIATED ADCC IN HODGKIN S DISEASE 781
toxicity of monocytes was independent of
the activity of the disease. Two of the 3
patients with the highest 51Cr release/103
NSE+ cells (Figure) were in a clinically
inactive state of the disease. In contrast,
a correlation has been reported between
enhanced monocyte suppressor cells and
disease activity (Hillinger & Herzig, 1978).
Previous investigations of monocyte
function in HD have shown impairment of
this particular cell type. Urbanitz et al.
(1975) found reduced phagocytosis in
patients with advanced HD and Leb &
Merritt (1978) described decreased mono-
cyte chemotactic response and monocyte
bactericidal activity in that disorder.
Recently, monocyte suppressor function
was found to be significantly higher in
HD, possibly impairing cellular immunity
(Hillinger & Herzig, 1978).
Our finding ofincreased cytolytic mono-
cyte activity indicates that monocyte
function is not generally impaired in HD
but restricted to certain functions of this
cell type. However, the question remains
whether the increased cytolytic activity of
monocytes in vitro actually represents the
patients' response to an increasing number
oftumour cells or, possibly, to an unknown
infectious agent.
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